



Contacts: Inviragen: Dr. Dan Stinchcomb, (970) 372-4754
 Colorado BioScience Association: Christine Shapard, (303) 592-4089

Inviragen Wins 2007 Rising Star Company Award

Fort Collins, CO

December 7, 2007

Inviragen received the “Rising Star” company award given to the company that demonstrated the most potential in 2007 at the BioWest meeting today. In its introduction, the Colorado BioScience Association noted that Inviragen had grown substantially since it won the Venture Showcase competition in at the same meeting in 2005. Highlighted were the opening of Inviragen’s office and laboratory facilities in Colorado, the worldwide exclusive license to dengue and West Nile vaccine technologies obtained from the CDC, and Inviragen’s manufacturing agreement with Shantha Biotechnic, one of India’s leading vaccine manufacturers. The award description noted that Inviragen received a prestigious five-year Cooperative Partnership grant from the National Institute of Allergy and Infectious Disease (NIAID), that Inviragen received funding from the S. Korea-based Pediatric Dengue Vaccine Initiative (PDVI) to accelerate the development and introduction of its dengue vaccine, and that Inviragen’s West Nile vaccine was chosen for further product development by the Rocky Mountain Regional Center of Excellence in Biodefense and Infectious Disease Research.

“We are very honored to receive this award from our peers in Colorado biotechnology,” said Dr. Dan Stinchcomb, Inviragen’s Chief Executive Officer. “These accomplishments could not have been made without the help of many in the community. We would particularly like to thank our investors for their support, our board and advisors, and our scientific colleagues and collaborators at the Centers for Disease Control, Colorado Statue University, Shantha Biotechnic in India, the Rocky Mountain Regional Center of Excellence and at University of Wisconsin. Inviragen

also received critical advice and support from both the Fort Collins Technology Incubator and Fitzsimmons BioBusiness Partners. Last but not least, I personally would like to thank all of Inviragen's employees for their dedication and contributions to the goal of applying cutting edge vaccine technology to global public health issues."

About Inviragen

Co-founded by Dr. Jorge Osorio and Dr. Dan Stinchcomb, Inviragen is developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen is developing a vaccine to protect against dengue fever for global markets, a vaccine to protect against West Nile for the U.S. markets, a combination plague and smallpox vaccine for biodefense, and an avian influenza vaccine. InViragen has offices in Fort Collins, Colorado and Madison, Wisconsin. Please see www.inviragen.com for more details.